These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30703267)

  • 21. Bioequivalence of thyroid preparations: the final word?
    Gibaldi M
    AAPS J; 2005; 7(1):E59-60. PubMed ID: 16493834
    [No Abstract]   [Full Text] [Related]  

  • 22. The generic drug approval process.
    Rheinstein PH
    Am Fam Physician; 1993 Dec; 48(8):1357-60. PubMed ID: 8249762
    [No Abstract]   [Full Text] [Related]  

  • 23. Hatch-Waxman Turns 30: Do We Need a Re-Designed Approach for the Modern Era?
    Kesselheim AS; Darrow JJ
    Yale J Health Policy Law Ethics; 2015; 15(2):293-347. PubMed ID: 26333236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory status of medicinal products for human beings in the European Union. The role of generic products.
    Minghetti P
    Pharmacol Res; 1996; 34(1-2):3-7. PubMed ID: 8981548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial responses to recommendations of the Blue Ribbon Committee on Generic Medicines.
    Heller WM
    Am J Hosp Pharm; 1993 Feb; 50(2):318-22. PubMed ID: 8480792
    [No Abstract]   [Full Text] [Related]  

  • 26. What's in a name? Generics and the persistence of the pharmaceutical brand in American medicine.
    Greene JA
    J Hist Med Allied Sci; 2011 Oct; 66(4):468-506. PubMed ID: 20858701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generic bioequivalence: a scientific consensus needed.
    Am Fam Physician; 1987 Feb; 35(2):91, 95. PubMed ID: 3812175
    [No Abstract]   [Full Text] [Related]  

  • 28. How good are our drugs?
    Miller LC
    Am J Hosp Pharm; 1970 May; 27(5):367-74. PubMed ID: 5422276
    [No Abstract]   [Full Text] [Related]  

  • 29. Physicians are concerned about generic drug bioequivalence, but often unaware of FDA standards.
    Am J Health Syst Pharm; 1997 Dec; 54(24):2799-800. PubMed ID: 9428948
    [No Abstract]   [Full Text] [Related]  

  • 30. Understanding bioequivalence testing.
    Benet LZ
    Transplant Proc; 1999 May; 31(3A Suppl):7S-9S. PubMed ID: 10330950
    [No Abstract]   [Full Text] [Related]  

  • 31. A shift on "pay for delay"--reopening doors for pharmaceutical competition?
    Hemphill Kraus EJ
    N Engl J Med; 2012 Nov; 367(18):1681-3. PubMed ID: 23113478
    [No Abstract]   [Full Text] [Related]  

  • 32. Generic drugs. Save money--but is there a cost?
    Roberts SS
    Diabetes Forecast; 2002 Nov; 55(11):51-3. PubMed ID: 14768605
    [No Abstract]   [Full Text] [Related]  

  • 33. Trying times for generic medicines in the USA.
    Lancet; 2013 Mar; 381(9872):1072. PubMed ID: 23540840
    [No Abstract]   [Full Text] [Related]  

  • 34. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality?
    Marsh DA; Hoar ME
    Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioequivalence/bioavailability retention samples.
    Ransom C
    Qual Assur; 1993; 2(1-2):42-3. PubMed ID: 8156218
    [No Abstract]   [Full Text] [Related]  

  • 36. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA moves closer to new requirements for NTI drugs.
    Traynor K
    Am J Health Syst Pharm; 2011 Sep; 68(17):1568-9, 1570. PubMed ID: 21856797
    [No Abstract]   [Full Text] [Related]  

  • 38. Meeting report: an exploration into the scientific and regulatory aspects of pharmaceutical drug quality in the United States.
    Flavin BM; Happe LE; Hatton RC
    Expert Opin Drug Saf; 2022 Feb; 21(2):167-170. PubMed ID: 34915789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opportunities and Challenges Related to the Implementation of Model-Based Bioequivalence Criteria.
    Seng Yue C; Ozdin D; Selber-Hnatiw S; Ducharme MP
    Clin Pharmacol Ther; 2019 Feb; 105(2):350-362. PubMed ID: 30375647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefits and liabilities of generic prescribing.
    Lee AM
    W V Med J; 1972 Jun; 68(6):161-6. PubMed ID: 4504384
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.